Inhibitory FcγRIIb and CD20 internalization

Ian Dransfield

Research output: Contribution to journalComment/debate

Abstract / Description of output

In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (e.g., rituximab) undergo Fcg receptor IIb (FcgRIIb)–mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based therapeutics (see figure).

Original languageEnglish
Pages (from-to)606-7
Number of pages2
JournalBlood
Volume123
Issue number5
DOIs
Publication statusPublished - 30 Jan 2014

Keywords / Materials (for Non-textual outputs)

  • Antibodies, Monoclonal
  • Humans
  • Receptors, IgG

Fingerprint

Dive into the research topics of 'Inhibitory FcγRIIb and CD20 internalization'. Together they form a unique fingerprint.

Cite this